Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 2.79B P/E - EPS this Y -130.70% Ern Qtrly Grth -
Income -3.99M Forward P/E -16.65 EPS next Y -21.90% 50D Avg Chg -
Sales 239.72M PEG -0.55 EPS past 5Y - 200D Avg Chg 1.00%
Dividend N/A Price/Book 21.61 EPS next 5Y 47.44% 52W High Chg -26.00%
Recommedations 2.90 Quick Ratio 8.76 Shares Outstanding 65.90M 52W Low Chg 16.00%
Insider Own - ROA -1.11% Shares Float 44.54M Beta 0.02
Inst Own 30.59% ROE -0.15% Shares Shorted/Prior 1.46M/1.45M Price 41.79
Gross Margin -0.66% Profit Margin 88.31% Avg. Volume 168,869 Target Price 41.90
Oper. Margin -33.63% Earnings Date - Volume 110,786 Change -0.55%
About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Galapagos NV News
04/04/24 Galapagos showcases innovative approach in hematological cancer care with clinical and translational data presentations at EBMT congress 2024
04/03/24 After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
03/28/24 Galapagos publishes 2023 annual report and announces Annual and Extraordinary Shareholders’ Meetings
03/26/24 Galapagos appoints Andrew Dickinson as Non-Executive Non-Independent Director to its Board
03/18/24 Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
03/17/24 11 Oversold Biotech Stocks To Buy Right Now
02/24/24 Galapagos NV (NASDAQ:GLPG) Q4 2023 Earnings Call Transcript
02/22/24 Galapagos announces full year 2023 results and outlook for 2024
02/22/24 Frontier Medicines Announces Oversubscribed $80 Million Series C Financing to Support Progress of Clinical-Stage Pipeline
02/15/24 Galapagos presents at EBMT-EHA annual meeting 2024
01/31/24 Galapagos completes transaction to transfer Jyseleca® business to Alfasigma
01/04/24 Galapagos enters into strategic collaboration agreement with Thermo Fisher Scientific to further expand its decentralized CAR-T manufacturing network in the U.S.
01/03/24 European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments
01/03/24 Galapagos establishes strategic collaboration with BridGene Biosciences to expand small molecule drug discovery in oncology
01/03/24 BridGene Biosciences Announces Strategic Collaboration with Galapagos to Discover Small Molecule Drugs for Oncology Targets
01/02/24 Galapagos signs agreement to transfer Jyseleca® business to Alfasigma
12/19/23 Galapagos announces start of PAPILIO-1 Phase 1/2 multiple myeloma study of point-of-care manufactured BCMA CAR-T candidate, GLPG5301
12/13/23 Best Momentum Stocks to Buy for December 13th
12/09/23 Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101
12/07/23 Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023
GLPG Chatroom

User Image PhaseHaiko Posted - 2 days ago

@Hailight Nächster Inso-Zock dann $GLPG natürlich haben sich Sharedeals Profis hier schon zu 60$ massiv eingedeckt und feiern bereits die Halbierung des Kapitals! Euer Haiko, euer NoGainerClub.

User Image NoGainer1 Posted - 1 week ago

$GLPG dummies ;D

User Image DonCorleone77 Posted - 2 weeks ago

$GLPG 3 of 3 - Galapagos announces clinical/ translational data on hematological cancer care ...."We believe that the preliminary safety and efficacy data from our ongoing Phase 1/2 studies with our CD19 CAR-T therapy candidates in patients with relapsed/refractory NHL, CLL and RT, combined with our unique, innovative decentralized manufacturing approach that enables a seven-day vein-to-vein time, support the promise of GLPG5101 and GLPG5201 in addressing the critical needs of patients facing poor prognosis."

User Image DonCorleone77 Posted - 2 weeks ago

$GLPG 2 of 3 - Galapagos announces clinical/ translational data on hematological cancer care ....The primary objective of the Phase 2 part of the studies is to assess the Objective Response Rate ORR and the secondary objectives include the analysis of the Complete Response CR , duration of response, progression free survival, overall survival, safety, pharmacokinetic profile, and feasibility of point-of-care manufacturing. GLPG5101 and GLPG5201 are second generation anti-CD19/4-1BB CAR-T product candidates, administered as a single fixed intravenous dose. "We are committed to accelerating breakthrough innovations to extend the reach of CAR-T therapies to patients with rapidly progressing cancers," said Dr. Jeevan Shetty, M.D., Head of Clinical Development Oncology at Galapagos....

User Image DonCorleone77 Posted - 2 weeks ago

$GLPG 1 of 3 - Galapagos announces clinical/ translational data on hematological cancer care Galapagos announced that four abstracts, including two oral presentations on encore preliminary clinical and translational data for its seven-day vein-to-vein CAR-T product candidates GLPG5101 and GLPG5201, will be presented at the 50th Annual Meeting of the European Society for Blood and Marrow Transplantation EBMT to be held in Glasgow, UK, on 14-17 April 2024. ATALANTA-1 and EUPLAGIA-1 are ongoing Phase 1/2 open-label, multi-center studies designed to assess the safety, efficacy and feasibility of point-of-care manufactured GLPG5101 and GLPG5201 in patients with relapsed/refractory NHL, and relapsed/refractory CLL and RT, respectively. The primary objective of the Phase 1 part of the studies is to evaluate the safety and preliminary efficacy to determine the recommended dose for the Phase 2 part of the study....

User Image NoGainer1 Posted - 2 weeks ago

$GLPG hoffentlich noch niemand gekauft den schrott ;D

User Image tradingtwenty Posted - 3 weeks ago

Top 5 oversold stocks that have trended in the past 24 hours: $SIRI 21.99 🔥 $GLPG 25.96 $BRZE 27.74 $NIO 28.14 $LFCR 28.67 Values range from 0 to 100, where 30 or below is oversold and 70 or above overbought. Link: https://tradingtwenty.com/dashboard/trending/past

User Image RallyRaider Posted - 03/31/24

$GLPG https://whalewisdom.com/stock/glpg sort by qtr first owned and avg price paid. A lot of structural change is happening here---- pair that with the gigantic cash pile they are sitting on. They are anticipating a turnaround. Makes no sense to sit at 33$. Caution: might get boring and take some time.

User Image NoGainer1 Posted - 03/28/24

$GLPG club dummies von sharedeals auch hier seit jahren nur noch am hoffen ;D

User Image AnaChart Posted - 03/28/24

$GLPG https://anachart.com/wp-content/uploads/ana_temp/1711627280_soc-img.jpg

User Image erevnon Posted - 03/28/24

B of A Securities downgrades Galapagos $GLPG from Neutral to Underperform and lowers the price target from $41 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image Stocksrunner Posted - 1 month ago

Technical Watch 📈 $KTOS crosses below 200-day moving average at $16.79, currently trading -1.1% $ADBE in 9.9% downtrend over last 4 weeks, now oversold according to analysts $MTTR -28.3% over last month, oversold conditions signal potential reversal $RBLX falls through 200-DMA of $37.21, down 6.2% on the day $GLPG -14.4% over 4 weeks but now oversold, analysts see turnaround potential

User Image Aigner_Andreas Posted - 1 month ago

#DeathCross $GLPG at 34.46 R13 HiLo 20% T1Y 55 hold 3.1 DIV N/A #Galapagos #stocks #trading #finance #market

User Image erevnon Posted - 1 month ago

Morgan Stanley assumes Galapagos $GLPG at Equal-Weight and a price target of https://marketsblock.com/stock-upgrades-and-downgrades/

User Image RallyRaider Posted - 1 month ago

$GLPG give me a sign already.... so much great change happening all while sitting on a big pile of gold (cash)

User Image Aigner_Andreas Posted - 1 month ago

TD BUY $GLPG at 34.66, Supp 34.66 Resis 39.66 R14 HiLo 22% T1Y 55 hold 3.1 DIV N/A #Galapagos #stocks #trading #finance #market

User Image tonneke Posted - 02/29/24

$GLPG I also thought I was smart and bought 100 for 35.60 😂😂 lid on my nose

User Image TickerDD_com Posted - 02/29/24

From 2/26/2024, looking back across 22 Month-Ends for GLPG, Percentage Change of Average Monthly Price had More Negatives (59%) while Percentage Change of Average Monthly Volume had All Positives (100%) $GLPG #GLPG #GLPGStock #TickerDD #GLPGPrice https://www.youtube.com/watch?v=jdSUaQvYJ3g

User Image Thorilium Posted - 02/29/24

$CYDY this company could be in for a $PFE $GLPG $MRNA $NVAX run - longest clinical hold in history of the FDA lifted, if you want a save drug, this one is turned upside and inside down by the FDA.

User Image NoGainer1 Posted - 1 month ago

$GLPG ;D

User Image psychohaiko Posted - 1 month ago

$GLPG coverage beendet, wir hatten ja hier schon lange zu Positionen um die 1% Depot-Gewichtung geraten! Weitere Kerbe im Zauberstab des Abraham Potter. HexHex.

User Image Doozio Posted - 2 months ago

$GLPG chop chop huckleberries. 2020FOUR 🧠⏰

User Image HDmen Posted - 2 months ago

$GLPG https://www.glpg.com/press-releases/galapagos-presents-at-ebmt-eha-annual-meeting-2024/

User Image StockInvest_us Posted - 2 months ago

Signal alert: $GLPG - PivotPoint bottom https://stockinvest.us/l/MpRbhpObIP

User Image Aigner_Andreas Posted - 01/25/24

#GoldenCross $GLPG at 38.28 R9 HiLo 50% T1Y 55 hold DIV N/A #Galapagos #stocks #trading #finance #market

User Image StockAutomatePro Posted - 3 months ago

$GLPG The stock market doesn't look optimistic based on the chart. We alerted the SELL signal at $41.89 and we were able to close this one with profit at $37.67 🎲

User Image JJ_Trades Posted - 3 months ago

$GLPG what makes this go over $50 again I don’t see it.

User Image Aigner_Andreas Posted - 3 months ago

TF SELL $GLPG at 38.82 : 39.15 MidCap -4% Shp 0.71 S 8.33 N 1.29 RSI 41.67% SRSI 0% ADXR 26.16 #stocks #trading #finance #market

Analyst Ratings
Morgan Stanley Equal-Weight Apr 22, 24
B of A Securities Underperform Apr 1, 24
B of A Securities Underperform Mar 28, 24
B of A Securities Neutral Jan 2, 24
Morgan Stanley Equal-Weight Aug 7, 23
Morgan Stanley Equal-Weight Aug 1, 23
Morgan Stanley Equal-Weight Jul 31, 23
Morgan Stanley Equal-Weight Jul 24, 23
Morgan Stanley Equal-Weight Jul 17, 23